bioecon Member area
Technology · Health & biomedicine / Diagnostics & medtech

Nanofluidic Point-of-Care Assays

Micro- and nanofluidic point-of-care cartridge platforms achieving rapid capillary separation of whole blood and digital single-molecule fluorescence detection, delivering quantitative multi-biomarker sepsis readouts in under 10 minutes directly in the emergency department.

Medicine & Pharmaceuticals Maturity 7/9 Risk: low Diagnostics Medical devices & implants Pharma & biologics CH · EU · US · CN verified 2026-11-22 · 1 Sources (0 independent)

1 · What it gives

Nanofluidic point-of-care assays represent an essential technological leap in in vitro diagnostics (IVD), transitioning quantitative biomarker analysis from centralized core clinical laboratories directly to emergency departments and intensive care units. By confining fluidic interactions within nanometer-scale channels (100–500 nm depth)—where molecular diffusion distances collapse to scales comparable to the Debye length—these platforms accelerate biomolecular collision kinetics by orders of magnitude.

Utilizing capillary action to passively separate plasma from a single drop (50 µL) of whole blood without centrifugation, commercial nanofluidic biosensors (e.g. Abionic abioSCOPE) quantify critical acute biomarkers such as Pancreatic Stone Protein (PSP) for sepsis detection in under 5 minutes with sub-picomolar analytical sensitivity, allowing clinicians to initiate life-saving interventions up to 72 hours before overt clinical deterioration.

The key directions of this technology are:

  1. Nanoscale Spatial Confinement & Accelerated Kinetics: Guiding fluorescently labeled biomolecular complexes through 100–500 nm nanofluidic slits, reducing Brownian diffusion distances to sub-micron scales and shortening incubation from hours to seconds.
  2. Passive Capillary-Driven Plasma Separation: Integrating microstructured porous filtration matrices that passively arrest erythrocytes and platelets, streaming pristine cell-free plasma into sensing nanochannels without requiring electric motors or centrifuges.
  3. Ultra-Rapid Sepsis & Acute Biomarker Detection: Measuring Pancreatic Stone Protein (PSP), high-sensitivity cardiac Troponin I (hs-cTnI), and procalcitonin at the patient’s bedside, identifying clinical sepsis up to 48–72 hours prior to overt organ failure.
  4. Single-Use Injection-Molded COC Diagnostic Cartridges: Mass-manufacturing micro- and nanofluidic lab-on-a-chip cartridges via high-precision cyclic olefin copolymer (COC) injection molding with pre-stored lyophilized fluorescent antibody conjugates.

Sectoral value chain#

┌────────────────────────────────────────────────────────┐
│  Tier 1: Nanofabrication & Precision Polymer Molding   │
│  (Nano-imprint lithography, COC precision tooling)     │
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 2: Reagents & Fluorophore-Nanobody Chemistries   │
│  (Monoclonal antibodies, high-quantum-yield dye tags)  │
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 3: Disposable Nanofluidic Cartridge Assembly    │
│  (Plasma separation membrane, lyophilized bead deposition)
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 4: Portable Optical Readers & Biosensor Units    │
│  (Miniaturized laser-induced fluorescence, CMOS reader)│
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 5: Point-of-Care Clinical & Hospital Informatics │
│  (ICU / ED bedside deployment, HL7 / FHIR integration) │
└────────────────────────────────────────────────────────┘

Value chain levels#

LevelDescriptionKey inputs/outputs
Nanostructured Substrates & ToolingPrecision master mold fabrication via electron-beam lithography and reactive ion etching, followed by high-throughput roll-to-plate or injection compression molding of cyclic olefin copolymer substrates with sub-micron channel definition.In: Optical COC resins, silicon master wafers, precision mold inserts.
Out: Dimensionally validated nanofluidic cartridge bases with 200 nm channel depth tolerances.
Biomarker Capture Probes & Fluorescent ReagentsHigh-affinity monoclonal antibodies and nanobodies conjugated to proprietary high-photostability organic fluorophores, lyophilized into stable micro-beads within the sample inlet.In: Monoclonal capture antibodies, fluorescent reporters, lyoprotectants.
Out: Lyophilized diagnostic reagent pellets stable for 12+ months at ambient storage.
Automated Micro-Nanofluidic Cartridge AssemblyUltrasonic welding and laser-bonding of porous blood separation membranes, capillary siphon channels, and nanofluidic sensor plates under ISO Class 7 cleanroom conditions.In: Molded COC plates, hydrophilic separation membranes, reagent pellets.
Out: Hermetically sealed, single-use, calibration-free point-of-care cartridges.
Compact Optical Readout InstrumentsPoint-of-care benchtop readers incorporating compact laser diodes, confocal or epi-fluorescent optical paths, motorized cartridge trays, and embedded digital signal processors.In: Solid-state laser diodes, optical bandpass filters, CMOS sensors, ARM processors.
Out: CE-IVD / FDA 510(k) certified point-of-care diagnostic analyzers.
Hospital Emergency & Critical Care IntegrationDirect wireless connectivity with Hospital Information Systems (HIS) and Laboratory Information Systems (LIS) via HL7/FHIR protocols for immediate bedside clinical decision support.In: Raw optical fluorescence signal arrays.
Out: Quantitative clinical biomarker values (pg/mL), sepsis risk indices, automated EMR records.

Cross-cutting technologies of the sector:

  • Point-of-Care Diagnostics (POCT): Supplies the core transducer and analytical engine for next-generation decentralized emergency diagnostics.
  • Microfluidics & Lab-on-a-Chip: Provides the upstream sample handling, blood separation, and passive capillary valving feeding into nanofluidic sensing zones.
  • Digital Biosensors & Single-Molecule Counting: Shares confocal fluorescence optics and ultra-sensitive photon detection algorithms with digital immunoassay platforms.

2 · What it replaces 2 · matched by industry

D2E–On-farm culture, PCR panels, rapid tests and veterinary laboratory services for livestock and aquaculture — treat what is diagnosed instead of blanket and prophylactic antibiotic treatment
Replaces: Blanket treatment of every clinical mastitis case, group metaphylaxis on suspicion, prophylactic antibiotics in hatcheries and ponds, …
DIAG
D2E4Crop disease forecasting models, spore traps, pheromone and smart pest traps and field diagnostics — spray when risk is real instead of calendar-based fungicide and insecticide programmes
Replaces: Fixed-interval ("calendar") protective fungicide sprays and routine insecticide applications regardless of pest pressure
EAC

3 · How to implement 4 steps

  1. 1
    Nanoscale channel capillary patterning
    Precision injection-molding of cyclic olefin polymer cartridges containing sub-micron capillary retention gates and lyophilized fluorophore reagents.
  2. 2
    On-chip whole-blood plasma separation
    Separating blood cells from plasma via passive cross-flow filtration within 60 seconds without external pumps or centrifuges.
  3. 3
    Single-molecule fluorescence detection
    Utilizing laser-induced confocal spot illumination to quantify low-abundance sepsis biomarkers (procalcitonin, IL-6, presepsin) at picogram/mL limits.
  4. 4
    Clinical emergency turnaround validation
    Demonstrating sample-to-result turnaround under 10 minutes in intensive care and acute triage clinical studies.

4 · Who delivers

Matched suppliers (matched automatically)

Lonza GroupSwitzerlandProduceractive
NovartisSwitzerlandProduceractive
WELTEC BIOPOWERGermanyProduceractive
Bota Bio 恩和生物ChinaProduceractive

Leading companies and institutes (from the brief)

Company / InstituteCountryKey products / platformsTech featuresStatus 2026
Abionic🇨🇭 SwitzerlandabioSCOPE Platform / PSP Sepsis Test / hs-cTnISwiss nanofluidic biosensor pioneer delivering 5-minute Pancreatic Stone Protein sepsis and cardiac assayscommercial
Abbott Point of Care🇺🇸 United Statesi-STAT System / CHEM8+ / Troponin CartridgesDecentralized microfluidic electrochemical testing system deployed across emergency departments globallycommercial
Siemens Healthineers🇩🇪 Germanyepoc Blood Analysis / Atellica VTLiHandheld POCT platforms delivering lab-quality high-sensitivity troponin and critical blood gas testingcommercial
LumiraDx (Roche)🇬🇧 United Kingdom / 🇺🇸 USLumiraDx Platform & Strip CartridgesMicrofluidic point-of-care instrument providing quantitative immunoassay and coagulation menuscommercial
QuidelOrtho🇺🇸 United StatesTriage MeterPro SystemEstablished point-of-care fluorescence immunoassay reader for acute emergency triage and cardiac markerscommercial
Wondfo Biotech🇨🇳 ChinaAccre Microfluidic Chemiluminescence SystemLeading Chinese IVD manufacturer scaling integrated microfluidic POCT instruments for critical carecommercial

5 · Rules & route to market

Route into Russia / EAEU: DIAG · Rosselkhoznadzor
expert examination up to 70 working days plus registration steps
Information, not legal advice — confirm the procedure for your product. (2026-10-06)
United States

Sepsis Mandates & FDA De Novo Clearance Pathways#

  • In the US, hospital sepsis quality mandates (such as CMS SEP-1 bundle compliance) drive intense clinical demand for point-of-care diagnostic tools capable of identifying septic shock within the golden hour.
  • The FDA regulates rapid biomarker diagnostic devices under 21 CFR 866.3215, offering De Novo classification and 510(k) clearance pathways for novel host-response sepsis biomarkers (e.g. Pancreatic Stone Protein, PSP).
  • Major commercial players focus on integrating nanofluidic point-of-care analyzers directly into emergency department workflows to reduce overall hospital length of stay and intensive care admission rates.

European Union

Nanotech Innovation Hubs & Rigorous IVDR Class D Compliance#

  • Europe—headquartered around the Lake Geneva ‘Health Valley’ in Switzerland—is the technological cradle of nanofluidic biosensors, where EPFL spin-off Abionic pioneered commercial nanofluidic molecular diagnostics.
  • The EU In Vitro Diagnostic Regulation (IVDR 2017/746) places sepsis diagnostic devices into high-risk Class D or Class C categories, requiring stringent notified body conformity assessments and robust multicenter clinical trials.
  • European intensive care units widely utilize bedside PSP assays to guide antibiotic stewardship programs and monitor post-surgical infection trajectories.

China

Chest Pain & Critical Care POCT Center Expansion#

  • China’s National Health Commission has driven nationwide construction of accredited Chest Pain Centers and Trauma Centers across secondary and tertiary hospitals, requiring ultra-rapid troponin and sepsis testing in under 10 minutes.
  • Domestic IVD manufacturers (such as Wondfo, Maccura, and Getein) are advancing from lateral flow immunoassays to micro- and nanofluidic cartridge platforms to match central laboratory chemiluminescence precision.
  • NMPA fast-track review pathways prioritize domestically produced, micro-sample cartridge analyzers suitable for remote township health centers and mobile emergency ambulances.

6 · Money: tenders & grants

7 · Tech stack & innovations

  1. Nanofluidic Flow Cell & Molecular Confinement:
    • Cyclic olefin copolymer (COC) biochips featuring high-density arrays of parallel nanochannels (200 nm depth, 2 µm width).
    • Molecular confinement collapsing Brownian diffusion distances, enabling fluorescent antibody-antigen complexes to reach equilibrium in <120 seconds.
    • Hydrophilic surface graft-polymerization providing passive capillary filling velocities of 1–5 mm/s without external pumps.
  2. On-Cartridge Sample Conditioning & Reagents:
    • Integrated polysulfone or glass-fiber size-exclusion filtration membrane separating up to 99.8% of cellular blood components from 50 µL whole blood.
    • Lyophilized reagent matrices containing high-affinity monoclonal antibodies tagged with proprietary ultra-bright fluorophores.
    • Capillary siphon stop-valves ensuring precise sample metering and sequential delivery into the nanofluidic interrogation zone.
  3. Detection Optics & Embedded Processing:
    • Solid-state 532 nm / 635 nm laser diode excitation coupled to an integrated high-numerical-aperture epifluorescence optical train.
    • High-quantum-efficiency CMOS array detector capturing localized fluorescence emissions with picomolar signal-to-noise ratios.
    • Embedded ARM processor running real-time baseline subtraction, peak-area integration, and automated internal calibration curve matching.

Sources 1 · 0 independent · 1 producer sites

Producers' own sites 1

  1. www.swissbiotech.org producer checked 2026-11-22